Large pharma companies at FoG London 2027

Jan 27–28, 2027 London, UK ~8.3k attendees Website

11 large pharma companies are at FoG London 2027 — 17 presentations on the program and 1 with a booth in the exhibit hall. Most represented: GSK (5 on the program), AstraZeneca (5 on the program), UCB (3 on the program). 5 of them have their own page in this guide. As of Oct 29, 2026.

All 243 organizations at FoG London 2027 →

Topic
Top represented
Showing 1–11 of 11 organizations
OrganizationFoG London 2027 Attendance
GSK
London, UK
Large pharma
Global biopharmaceutical company developing vaccines and specialty medicines in infectious disease, HIV, oncology and immunology.
Talk
Wed Jan 27
14:30–15:00
Making Biobank Data Useful for Drug Discovery
How genetic data from large biobanks can point to promising drug targets and strengthen the evidence behind clinical development.
Talk
Wed Jan 27
14:30–15:00
Protein AI Models for Drug Discovery
How AI models trained on protein sequences and structures could help explain disease and find drug targets.
Talk
Wed Jan 27
16:30–17:00
Data Science Opportunities in Oncology Discovery & Translation
How combining genomic data, gene-disruption experiments and real-world patient records can link cancer drug targets to mechanisms and patient groups.
Panel
Wed Jan 27
17:30–18:00
Using High Dimensional Multi-Omic Data in Drug Discovery & Translational Research
How combining several layers of molecular data can reveal drug targets and biomarkers, and what slows their path to the clinic.
with Imperial College London, DISCO Pharmaceuticals
Panel
Thu Jan 28
11:30–12:00
Are We Seeing Real Breakthroughs from AI, or Just Faster Trial and Error?
Whether AI-discovered drugs now reaching mid-stage trials are truly better molecules, and how success for AI in drug discovery should be measured.
with UCB, Ipsen, Entelo Bio +1 more
AstraZeneca
Cambridge, UK
Large pharma
Global biopharmaceutical company with medicines in oncology, rare disease, cardiovascular, renal, respiratory and immunology.
Panel
Wed Jan 27
17:30–18:00
Choosing the Right Sequencing Technology: Short Reads, Long Reads & Beyond
How researchers weigh short-read and long-read sequencing on accuracy, resolution, throughput and cost, and when to combine them.
with Relation Therapeutics, Wellcome Sanger Institute
Talk
Wed Jan 27
17:30–18:00
From Human IN the Loop to Human ON the Loop
Why scientists should help build AI tools from the start, and why keeping them reliable needs ongoing scientific oversight.
Also
Presenting at the meeting, beyond the sessions above
UCB
Brussels, Belgium
Large pharma
Belgian biopharmaceutical company developing medicines for neurology and immunology conditions.
Panel
Thu Jan 28
11:30–12:00
Are We Seeing Real Breakthroughs from AI, or Just Faster Trial and Error?
Whether AI-discovered drugs now reaching mid-stage trials are truly better molecules, and how success for AI in drug discovery should be measured.
with GSK, Ipsen, Entelo Bio +1 more
Talk
Thu Jan 28
16:10–16:40
Synthetic Data in Clinical Development: Enabling the Next Generation of Scientific Evidence
How industry and regulators are setting rules for using synthetic, computer-generated data in drug development, from trial design to hard-to-study patient groups.
Also
Presenting at the meeting, beyond the sessions above
Novo Nordisk
Bagsværd, Denmark
Large pharma
Danish pharmaceutical company focused on diabetes, obesity and other serious chronic diseases.
Talk
Thu Jan 28
12:30–13:00
Session (details to come)
How biology-led AI could turn many kinds of data into evidence strong enough to choose and prioritise drug targets early in research.
Talk
Thu Jan 28
15:10–15:40
Teaching AI to Understand Biology: From Cellular Perturbations to Intelligent Drug Discovery
Whether AI models, including large language models, can predict cell responses to drugs, reason about biology and run bioinformatics tasks reliably.
Large pharma
AstraZeneca's rare disease unit, developing and selling medicines for rare conditions, including complement-inhibitor therapies.
Panel
Wed Jan 27
12:30–13:00
Designing the Next Generation of Rare Disease Therapies: From Advanced Genomics to AI-Enabled Therapeutic Innovation
How better knowledge of disease genetics and AI could shape the design of more precise, personalised treatments for rare diseases.
with ABPI, MeiraGTx, Lir Therapeutics
Bayer
Leverkusen, Germany
Large pharma
Life science group with pharmaceuticals, consumer health and crop science divisions, including cell and gene therapy programmes.
Panel
Wed Jan 27
17:30–18:00
How Can We Bridge the Gap from Discovery to GMP Manufacturing?
When and how cell and gene therapy developers should plan manufacturing and regulation so a lab process can scale without losing quality.
with Resolution Therapeutics, Axovia Therapeutics, TTP
Boehringer Ingelheim
Ingelheim, Germany
Large pharma
Family-owned pharmaceutical company developing human and animal health medicines.
Talk
Thu Jan 28
16:40–17:10
Multimodal Identification of Disease Segments
How machine learning on large blood protein datasets can sort patients into disease subtypes that standard diagnostic tests miss.
Ipsen
Boulogne-Billancourt, France
Large pharma
French biopharmaceutical company with marketed medicines in oncology, rare disease and neuroscience.
Panel
Thu Jan 28
11:30–12:00
Are We Seeing Real Breakthroughs from AI, or Just Faster Trial and Error?
Whether AI-discovered drugs now reaching mid-stage trials are truly better molecules, and how success for AI in drug discovery should be measured.
with GSK, UCB, Entelo Bio +1 more
Novartis
Basel, Switzerland
Large pharma
Swiss pharmaceutical company with medicines in oncology, cardiovascular, immunology and neuroscience, including cell and gene therapies.
Talk
Wed Jan 27
15:30–16:00
Applying AI for Oncology Drug Target Identification & Prioritisation
How AI and single-cell, spatial and other molecular data can find and rank new cancer drug targets worth testing in the lab.
Servier
Suresnes, France
Large pharma
French pharmaceutical group governed by a foundation, developing medicines in oncology, cardiometabolic and other diseases.
Talk
Wed Jan 27
12:30–13:00
Leveraging Genomic Sequence-to-Function Language Models for the Design of Antisense Oligonucleotides
How AI models that predict what a DNA sequence does could help design antisense oligonucleotides, with early tests reproducing a known drug's effect.
Octapharma
Lachen, Switzerland
Large pharma
Privately owned Swiss maker of human protein medicines derived from plasma and human cell lines.
Booth
Exhibiting at Booth 13

Explore the full FoG London 2027 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in London. Leave your work email and we’ll be in touch.

Privacy

Download the full FoG London 2027 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from large pharma companies

Tell us what you sell and we’ll find the people at these large pharma companies most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse FoG London 2027 by

Exhibit hall

Not affiliated with or endorsed by Front Line Genomics or the Festival of Genomics. Submit a correction